<DOC>
	<DOCNO>NCT01109524</DOCNO>
	<brief_summary>The purpose study determine U.S. manufacture Cetuximab safely use treatment Non-Small Cell Lung Cancer combination Cisplatin Vinorelbine .</brief_summary>
	<brief_title>Safety Study Cetuximab Combination With Cisplatin Vinorelbine Treat Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>NonSmall Cell Lung Cancer ( NSCLC ) , Stage IV ( per American Joint Committee Cancer ( AJCC ) Staging Manual , Seventh Edition ) recurrent disease follow surgery and/or radiation therapy Evaluable measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Uncontrolled Central Nervous System ( CNS ) metastasis . Previous exposure monoclonal antibody , signal transduction inhibitor Epidermal growth factor receptor ( EGFR ) target therapy Concurrent malignancy Prior chemotherapy NSCLC Preexisting ascites grade ≥ 2 pericardial effusion grade ≥ 2 Superior vena cava syndrome contraindicate hydration White Blood Cells ( WBC ) &lt; 3,000/mm³ Absolute neutrophile count ( ANC ) &lt; 1,500/mm³ Platelet &lt; 100,000/mm³ Hemoglobin ( Hgb ) &lt; 9.0 g/dL Total bilirubin &gt; 1.5 x Upper limit normal ( ULN ) . Aspartate aminotransferase ( AST ) Alanineaminotransferase ( ALT ) &gt; 5.0 x ULN . Serum creatinine &gt; 1.25 x ULN calculate creatinine clearance &lt; 60mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>